Hosoya Tokuko, Oda Goshi, Nakagawa Tsuyoshi, Onishi Iichiroh, Hosoya Tadashi, Ishiguro Megumi, Ishikawa Toshiaki, Uetake Hiroyuki
Department of Breast Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Department of Pathology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
J Clin Med. 2021 Nov 26;10(23):5530. doi: 10.3390/jcm10235530.
Decorin (DCN), an extracellular matrix proteoglycan found in tumor surrounding tissues, is a natural inhibitor of tumor cell proliferation and invasion. We conducted a cross-sectional observation study to evaluate the association of the pathological stage with the levels of DCN in plasma or tumor surrounding tissue. Among 118 patients who underwent breast surgery, 35 were designated as carcinoma in situ (Stage 0), 39 were Stage I, and 44 were Stage II or III. The stromal expression of DCN was quantified using a semiquantitative digital image analysis after immunohistochemical staining. The concentration of DCN was evaluated with a specific ELISA. As we have previously shown, stromal DCN expression was attenuated in the patients with Stage I, whereas stromal and plasma DCN was elevated paradoxically in those with Stage II/III. The elevated plasma DCN is an independent predictive factor of Stage II/III by the multivariate logistic regression analysis. The plasma level of DCN was negatively correlated with stromal DCN expression only in patients with advanced disease (Stage II/III). The plasma level of DCN could become a useful biomarker for patients in the advanced stages. Extensive studies and further assessments are warranted for evaluating the prognostic significance and tumor characteristics to understand the clinical significances of stromal and systemic DCN.
核心蛋白聚糖（DCN）是一种存在于肿瘤周围组织中的细胞外基质蛋白聚糖，是肿瘤细胞增殖和侵袭的天然抑制剂。我们进行了一项横断面观察研究，以评估病理分期与血浆或肿瘤周围组织中DCN水平的关联。在118例行乳腺手术的患者中，35例被指定为原位癌（0期），39例为I期，44例为II期或III期。免疫组织化学染色后，采用半定量数字图像分析对DCN的基质表达进行定量。用特异性酶联免疫吸附测定法（ELISA）评估DCN的浓度。正如我们之前所表明的，I期患者的基质DCN表达减弱，而II/III期患者的基质和血浆DCN却反常升高。多因素逻辑回归分析显示，血浆DCN升高是II/III期的独立预测因素。仅在晚期疾病（II/III期）患者中，DCN的血浆水平与基质DCN表达呈负相关。DCN的血浆水平可能成为晚期患者有用的生物标志物。有必要进行广泛的研究和进一步评估，以评估其预后意义和肿瘤特征，从而了解基质和全身DCN的临床意义。
